Barclays lowered the firm’s price target on Tandem Diabetes to $39 from $62 and keeps an Overweight rating on the shares. The analyst says fans of Tandem have endured 12-18 months of challenges, reductions in outlook and the GLP-1-driven overhang. However, with three major products poised to emerge from ‘limited’ to full launch, 2024 “could be TNDM‘s year,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TNDM:
- Tandem Diabetes price target lowered to $35 from $50 at Craig-Hallum
- Tandem Diabetes price target lowered to $22 from $34 at TD Cowen
- Tandem Diabetes price target lowered to $25 from $40 at Piper Sandler
- Tandem Diabetes price target lowered to $20 from $32 at Baird
- Tandem Diabetes price target lowered to $21 from $30 at Wells Fargo